Pacira(US:PCRX) Globenewswire·2025-01-10 13:00Core Viewpoint - Pacira BioSciences, Inc. is focused on transforming into an innovative biopharmaceutical organization with a five-year growth plan aimed at becoming a leader in musculoskeletal pain management, reporting preliminary unaudited revenue of $701.0 million for 2024, up from $675.0 million in 2023 [1][2]. Group 1: Financial Performance - Preliminary unaudited total revenue for 2024 is reported at $701.0 million, an increase of 3.7% from $675.0 million in 2023 [1]. - Fourth quarter net product sales for EXPAREL reached $147.7 million in 2024, compared to $143.9 million in 2023, with volume growth and a price increase partially offset by a shift in vial mix and discounting [8]. - Full-year EXPAREL net product sales totaled $549.0 million in 2024, up from $538.1 million in 2023, driven by a 4% average daily volume growth [8]. Group 2: Growth Strategy - The company aims to achieve five objectives by 2030 under its "5x30" plan, focusing on growth, operational excellence, and addressing unmet patient needs in musculoskeletal pain [2]. - Pacira is committed to expanding its clinical pipeline with five novel programs in development and establishing five partnerships, including pipeline and commercial agreements [7]. Group 3: Product Performance - Fourth quarter ZILRETTA net product sales were $33.1 million in 2024, up from $28.7 million in 2023, while iovera° net product sales increased to $6.5 million from $6.0 million in the same period [8]. - Full-year ZILRETTA net product sales reached $118.1 million in 2024, compared to $111.1 million in 2023, and iovera° net product sales were $22.8 million, up from $19.7 million [8]. Group 4: Market Position - Pacira has treated more than three million patients annually and is experiencing a double-digit compounded annual growth rate in product revenue [7]. - The company is positioned to extend its leadership in non-opioid pain management with a best-in-class commercial portfolio generating significant cash flow [2].